Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

Title
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
Authors
Keywords
metformin, MEK, selumetinib, pimasertib, NSCLC
Journal
Oncotarget
Volume 7, Issue 4, Pages -
Publisher
Impact Journals, LLC
Online
2015-12-11
DOI
10.18632/oncotarget.6559

Ask authors/readers for more resources

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now